arrow
C

Charlene Supnet

Washington University School of Medicine
H指数:21
被引数:1,825

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

可溶性tau物种与阿尔茨海默病淀粉样斑块清除及tau病理的关系

2025-09-230
OAAI
Three versus six sessions of problem-solving training with or without boosters for care partners of adults with dementia (CaDeS): a randomised controlled optimization trial

三节与六节问题解决训练(含或不含强化训练)对痴呆成人照护者的比较研究(CaDeS):一项随机对照优化试验

2025-09-040
PREAI
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial

gantenerumab在DIAN-TU-001试验中对神经影像生物标志物的区域性影响

2025-07-140
OA
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease

显性遗传阿尔茨海默病中gantenerumab或solanezumab试验的免疫组化评估

2025-06-030
OAAI
Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease

运动与常染色体显性阿尔茨海默病生物标志物之间的纵向关联

2024-09-260
OA
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden

Α-突触核蛋白种子扩增测定法可检测常染色体显性遗传性阿尔茨海默氏病的Lewy体共病理,并取决于Lewy病理负担

2024-04-263
OA
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
2024-02-211
OA
Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease
2023-12-191
OAAI
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease

在显性遗传性阿尔茨海默氏病中抗淀粉样 β 单克隆抗体的2/3期临床试验中,11C-PiB和18F-florbetapir PET的纵向头对头比较

2023-04-057
OA